sampleMetabolic burn without training
98%+ · 1mg · Tablets · MW: 397.43
Bulk discount
3+ pcs
€128.25
−5%
5+ pcs
€121.50
−10%
10+ pcs
€114.75
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
SLU-PP-332 Tablets 1 mg × 30
ERR α/β/γ Pan-Agonist | Exercise Mimetic Research | Oral Tablet Format
In short
Studied for how it may help your body mimic the physical benefits of a workout. Research suggests it could boost your energy and improve endurance without actual exercise.
SLU-PP-332 is an investigational small molecule that acts as a triple agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ). At the molecular level, it activates specific genetic programs that stimulate mitochondrial biogenesis and fatty acid oxidation, mimicking the cellular processes that occur during endurance exercise. In laboratory settings and animal models, the compound is being studied for its potential to alter muscle fiber composition and regulate oxidative metabolism. This product is strictly for scientific research purposes and is not an approved medication for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Best sellers
Education
Related resources
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
SLU-PP-332 is a triple ERR agonist — the first small molecule to activate all three estrogen-related receptor isoforms with similar potency. ERRs are nuclear receptors that regulate oxidative metabolism, mitochondrial function, and fiber-type composition in skeletal and cardiac muscle. The compound is investigated as an 'exercise pill' candidate — a pharmacological mimic of the cellular adaptations driven by endurance training.
First-in-class triple ERR pan-agonist EC₅₀ vs ERRα ≈ 98 nM Murine data: improved exercise capacity Saint Louis University (Elgendy lab) — published in Nature Metabolism
Pan-agonism at ERRα, ERRβ, and ERRγ upregulates PGC-1α coactivation targets — driving mitochondrial biogenesis, fatty-acid β-oxidation enzymes, and a shift toward slow-twitch oxidative muscle phenotype. The transcriptional program overlaps substantially with that induced by endurance exercise.
Investigated for transcriptional mimicry of endurance training adaptations — mitochondrial biogenesis, oxidative fiber shift, and fatty-acid oxidation upregulation.
Limited safety data — preclinical only. No human pharmacovigilance signal has been established. Investigators should treat the compound with full research-compound caution, including standard exclusion criteria for unstudied nuclear receptor modulators (pregnancy, hormone-sensitive conditions).
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
A small-molecule pan-ERR agonist as an exercise mimetic
Mouse | Nature Metabolism 2023
Elgendy lab reported SLU-PP-332 reproduces key transcriptional and physiological adaptations of endurance training in mouse models.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
